HENLIUS (02696.HK) announced a collaboration and licensing agreement with Palleon, whereby both parties agree to global collaborative development and commercialization in their respective licensed regions for E-602 and combination therapy for the treatment of human diseases. This collaboration does not involve an upfront payment, with the company set to pay Palleon milestone payments totaling no more than 95.3 million USD, along with royalties calculated at 8%-12% of annual net sales.
復宏漢霖(02696.HK)與Palleon訂立合作及許可協議
HENLIUS (02696.HK) has entered into a collaboration and licensing agreement with Palleon.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated